ANQ 9040

Drug Profile

ANQ 9040

Latest Information Update: 25 Mar 1999

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Baxter International
  • Class Androstanes; Azasteroids; Muscle relaxants
  • Mechanism of Action Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Muscle hypertonia

Most Recent Events

  • 25 Mar 1999 No-Development-Reported for Hypertonia in USA (Unknown route)
  • 07 Nov 1995 Phase-I clinical trials for Hypertonia in USA (Unknown route)
  • 07 Nov 1995 Two studies have been added to the pharmacodynamics and adverse events sections ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top